Targeting Mutant BRAF with Vemurafenib in Relapsed or Refractory Hairy Cell Leukemia

BACKGROUND: BRAF-V600E is the genetic lesion underlying hairy cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy cell leukemia who relapsed after or were refractory to purine analogues. METHODS: We conducted in Italy and USA two phase-2 s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Tiacci, Enrico, Park, Jae H., De Carolis, Luca, Chung, Stephen S., Broccoli, Alessandro, Scott, Sasinya, Zaja, Francesco, Devlin, Sean, Pulsoni, Alessandro, Chung, Young Rock, Cimminiello, Michele, Kim, Eunhee, Rossi, Davide, Stone, Richard M., Motta, Giovanna, Saven, Alan, Varettoni, Marzia, Altman, Jessica K., Anastasia, Antonella, Grever, Michael R., Ambrosetti, Achille, Rai, Kanti R., Fraticelli, Vincenzo, Lacouture, Mario E., Carella, Angelo Michele, Levine, Ross L., Leoni, Pietro, Rambaldi, Alessandro, Falzetti, Franca, Ascani, Stefano, Capponi, Monia, Martelli, Maria Paola, Park, Christopher Y., Pileri, Stefano Aldo, Rosen, Neal, Foà, Robin, Berger, Michael F., Zinzani, Pier Luigi, Abdel-Wahab, Omar, Falini, Brunangelo, Tallman, Martin S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4811324/
https://ncbi.nlm.nih.gov/pubmed/26352686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1506583
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados